Physician profile
Mark A Stich
NPI 1336117514
$3,622.79
in general payments reported to CMS, 2019-2025
32 companies · $23.93 in 2025
The $23.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $768 · 2021: $301 · 2022: $66.80 · 2023: $217 · 2024: $364 · 2025: $23.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $578.56 | 2019-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $390.97 | 2019-2024 | Capvaxive, Gardasil 9, Vaxneuvance |
| Novo Nordisk INC | $342.82 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $296.79 | 2019-2020 | |
| Amarin Pharma, INC. | $253.89 | 2019-2021 | |
| Abbott Laboratories | $249.99 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $196.37 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $185.76 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.93 | 2019-2020 | |
| Abbvie INC. | $141.58 | 2019-2023 | Qulipta |
| Novartis Pharmaceuticals Corporation | $132.70 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $107.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $64.66 | 2019-2020 | |
| Pfizer INC. | $60.88 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $52.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.40 | 2019 | |
| Astellas Pharma US INC | $40.67 | 2021-2025 | Veozah |
| Sanofi Pasteur INC. | $38.81 | 2019 | |
| Allergan, INC. | $31.99 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.44 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $25.64 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.54 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.89 | 2024 | Voquezna |
| Circassia INC. | $20.95 | 2019 | |
| Seqirus USA INC | $15.11 | 2019 | |
| Dexcom, INC. | $14.92 | 2024 | Dexcom G6 Transmitter |
| Global Blood Therapeutics, INC. | $12.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.62 | 2021 | |
| Assertio Therapeutics, INC. | $11.06 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.